Triple Drug Therapy Shows Promise in Eliminating Pancreatic Tumors in Mice

A novel combination therapy targeting the KRAS pathway at multiple points has demonstrated the ability to eliminate pancreatic tumors in mouse models, offering a potential strategy to overcome treatment resistance in this aggressive cancer.

Overcoming Treatment Resistance in Pancreatic Cancer

Pancreatic cancer is notoriously challenging to treat, with tumors often developing resistance to existing therapies within months. Researchers at the National Cancer Research Centre (CNIO) in Spain have reported a breakthrough in preventing this resistance using a three-drug combination therapy. Even as clinical trials are still some time away, the findings, published in Proceedings of the National Academy of Sciences, suggest a promising new avenue for treatment development.

The KRAS Pathway and a Multi-Pronged Approach

More than 90% of pancreatic cancers are driven by mutations in the KRAS gene. Recent advancements have led to the approval of drugs targeting this gene, marking the first significant improvement in pancreatic cancer treatment in over 50 years. However, tumors frequently adapt and become resistant to these drugs.

The CNIO team, led by Mariano Barbacid, focused on circumventing this resistance by simultaneously blocking the KRAS signaling pathway at three different points. This approach aims to prevent cancer cells from bypassing the blockage by interrupting multiple steps in the pathway. In mouse models, genetically removing three molecules involved in KRAS signaling resulted in the permanent elimination of pancreatic tumors.

The Three-Drug Combination

To translate this concept into a viable treatment, the researchers combined three agents: the experimental KRAS inhibitor daraxonrasib, the approved lung cancer drug afatinib, and a protein degrader known as SD36.

Testing this combination in three separate mouse models of pancreatic ductal adenocarcinoma yielded strong and lasting tumor regression without significant toxicity, according to the study published in PNAS.

Future Directions and Clinical Trials

While these results are encouraging, Barbacid emphasizes that further research is needed before the therapy can be tested in humans. “Although experimental results like those described here have never been obtained before, we are still not in a position to carry out clinical trials with the triple therapy,” he stated. Adapting the three-drug combination for clinical employ will require additional refinement and development.

Despite these limitations, the findings offer hope for new therapeutic options to improve outcomes for patients with pancreatic ductal adenocarcinoma in the future.

Key Takeaways

• A three-drug combination therapy has shown the ability to eliminate pancreatic tumors in mouse models.
• The therapy targets the KRAS pathway at three different points to prevent treatment resistance.
• The combination includes the experimental KRAS inhibitor daraxonrasib, afatinib, and SD36.
• Further research is needed before clinical trials can initiate.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.